As evidenced by a debate at the CHEST Annual Meeting 2023, the pulmonology community disagrees on whether the overlap of asthma and chronic obstructive pulmonary disease (COPD) is a distinct entity ...

Gordon Stewart-Harrison recalls his first experience with chronic obstructive pulmonary disease (COPD) when he was shoveling snow on his driveway. After just a few moments, he was completely out of ...

FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...

Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that affects millions of people in the United States and around the world. Despite its prevalence, many individuals ...

COPD 5-year mortality was most likely in patients receiving long-term oxygen therapy, oral corticosteroids, and triple therapy. Increasing treatment intensity levels (TILs) in patients with chronic ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...

WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...